COMP <GO>
PAHC vs OCUL // EV/EBITDA & P/E VALUATION
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Ocular Therapeutix Inc. (NASDAQ) • 15-METRIC TALLY: PAHC 8
— OCUL 3
■ METRIC PARITY
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
LAST: $7.31 (+0.27%) • MKT CAP: $1.61B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. OCUL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | OCUL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 87.30% | -56.40 | OCUL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | -13.51% | +18.59 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | -60.00% | +68.50 | PAHC | /operating-margins <GO> |
| Net Profit Margin | 3.70% | -60.00% | +63.70 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | -18.50% | +45.90 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.00% | +1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 4.31 | -1.44 | OCUL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 3/9 | +5.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 42.3 | +14.60 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $1.61B | -$27.6M | OCUL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | OCUL REV | PAHC GROSS % | OCUL GROSS % | PAHC FCF | OCUL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $52.0M | 30.9% | 87.3% | $80.1M | -$216.9M |
| FY 2024 | $1.02B | $63.7M | 30.8% | 91.2% | $87.6M | -$136.0M |
| FY 2023 | $977.9M | $58.4M | — | — | $13.3M | -$70.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
OCUL // BETA —